ODAC Will Review Denosumab SRE Data If FDA Requires Advisory Committee
Executive Summary
FDA's Oncologic Drugs Advisory Committee will take the lead in reviewing Amgen's osteoporosis drug Prolia (denosumab) for prevention of skeletal-related events in advanced cancer patients if the agency chooses to take the drug to panel
You may also be interested in...
Is Two Too Few? Denosumab Advisory Cmte. Lacked Permanent Members
The Reproductive Health Drugs Advisory Committee reviewing Amgen's Prolia (densoumab) had the fewest permanent members on the panel it has had in the last five years
Amgen, FDA Ready For Another REMS Go Around With Prolia
Amgen brings a key commercial advantage to negotiations with FDA over a REMS plan for its osteoporosis drug denosumab: regulatory experience
Is Two Too Few? Denosumab Advisory Cmte. Lacked Permanent Members
The Reproductive Health Drugs Advisory Committee reviewing Amgen's Prolia (densoumab) had the fewest permanent members on the panel it has had in the last five years